Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) EPS (Weighted Average and Diluted) (2019 - 2025)

Ptc Therapeutics (PTCT) has 10 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.2 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 114.39% year-over-year to $0.2; the TTM value through Sep 2025 reached $8.0, up 234.68%, while the annual FY2025 figure was $7.78, 264.48% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.2 in Q3 2025 per PTCT's latest filing, down from $10.04 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $10.04 in Q1 2025 and bottomed at -$2.67 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.0, with a median of -$1.77 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 108.04% in 2021, then surged 936.67% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.02 in 2021, then fell by 16.83% to -$2.36 in 2022, then grew by 12.71% to -$2.06 in 2023, then surged by 58.74% to -$0.85 in 2024, then skyrocketed by 123.53% to $0.2 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.2 in Q3 2025, $10.04 in Q1 2025, and -$0.85 in Q4 2024.